Monopar Therapeutics Inc.

Monopar Therapeutics Inc.verified

MNPR

Price:

$0.6289

Market Cap:

$11.00M

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimm...[Read more]

Industry

Biotechnology

IPO Date

2019-12-19

Stock Exchange

NASDAQ

Ticker

MNPR

The PE Ratio as of May 2024 (TTM) for Monopar Therapeutics Inc. (MNPR) is -1.21

According to Monopar Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.21. This represents a change of 1.35% compared to the average of -1.19 of the last 4 quarters.

Monopar Therapeutics Inc. (MNPR) Historical PE Ratio (quarterly & annually)

How has MNPR PE Ratio performed in the past?

The mean historical PE Ratio of Monopar Therapeutics Inc. over the last ten years is -49.55. The current -1.21 PE Ratio has changed 144.21% with respect to the historical average. Over the past ten years (40 quarters), MNPR's PE Ratio was at its highest in in the December 2023 quarter at -0.70. The PE Ratio was at its lowest in in the March 2017 quarter at -185.13.

Quarterly (TTM)
Annual

Average

-49.55

Median

-13.73

Minimum

-232.93

Maximum

-0.56

Monopar Therapeutics Inc. (MNPR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Monopar Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 412.86%

Maximum Annual PE Ratio = -0.56

Minimum Annual Increase = -92.84%

Minimum Annual PE Ratio = -232.93

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.56-80.51%
2022-2.87-34.87%
2021-4.41-59.08%
2020-10.78-74.70%
2019-42.60-50.21%
2018-85.55412.86%
2017-16.68-92.84%

Monopar Therapeutics Inc. (MNPR) Average PE Ratio

How has MNPR PE Ratio performed in the past?

The current PE Ratio of Monopar Therapeutics Inc. (MNPR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-2.61

5-year avg

-12.24

10-year avg

-49.55

Monopar Therapeutics Inc. (MNPR) PE Ratio vs. Peers

How is MNPR’s PE Ratio compared to its peers?

Monopar Therapeutics Inc.’s PE Ratio is greater than Anebulo Pharmaceuticals, Inc. (-5.87), greater than Acrivon Therapeutics, Inc. Common Stock (-2.80), greater than PMV Pharmaceuticals, Inc. (-1.61), greater than Molecular Partners AG (-1.95), greater than Mineralys Therapeutics, Inc. (-6.03), greater than Candel Therapeutics, Inc. (-6.10), greater than Acurx Pharmaceuticals, Inc. (-2.42), less than Enochian Biosciences, Inc. (0), greater than scPharmaceuticals Inc. (-2.37), greater than DiaMedica Therapeutics Inc. (-5.68), less than Scopus BioPharma Inc. (-0.01), less than Pasithea Therapeutics Corp. (-0.41), less than AN2 Therapeutics, Inc. (-0.91), greater than Pharvaris N.V. (-12.09), greater than PepGen Inc. (-5.19), greater than Aerovate Therapeutics, Inc. (-5.78), greater than Adagene Inc. (-3.96), greater than Rezolute, Inc. (-3.11),

Build a custom stock screener for Monopar Therapeutics Inc. (MNPR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monopar Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Monopar Therapeutics Inc. (MNPR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Monopar Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Monopar Therapeutics Inc.'s PE Ratio?

How is the PE Ratio calculated for Monopar Therapeutics Inc. (MNPR)?

What is the highest PE Ratio for Monopar Therapeutics Inc. (MNPR)?

What is the 3-year average PE Ratio for Monopar Therapeutics Inc. (MNPR)?

What is the 5-year average PE Ratio for Monopar Therapeutics Inc. (MNPR)?

How does the current PE Ratio for Monopar Therapeutics Inc. (MNPR) compare to its historical average?